期刊论文详细信息
BMC Ophthalmology
Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis
Research
Arslan Tsai1  Pei-Chang Wu2  Wen-Chuan Wu3  Chien-Liang Wu4  Cheng-Kuo Cheng5  Ching-Yao Tsai6  Yun-Dun Shen7  Jiann-Torng Chen8 
[1] Clinical Development and Medical Affairs, Novartis Taiwan, Taipei City, Taiwan;Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan;Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan;Park One International Hospital, Kaohsiung City, Taiwan;Municipal Wan Fang Hospital, Taipei City, Taiwan;Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan;Taipei City Hospital, Taipei City, Taiwan;Institute of Public Health, National Yang Ming Chiao Tung University, Taipei City, Taiwan;Department of Business Administration, Fu Jen Catholic University, New Taipei City, Taiwan;Taipei Medical University-Shung Ho Hospital, New Taipei City, Taiwan;Kang-Ning General Hospital, Taipei City, Taiwan;Tri-Service General Hospital, Chenggong Road, Taipei City 114, Taiwan;National Defense Medical Center, Taipei City, Taiwan;
关键词: Anti-VEGF;    BCVA;    Clinical practice;    CRT;    nAMD;    RACER;    Ranibizumab;    Real-world;    Taiwan;    Treatment switch;    Treatment response;   
DOI  :  10.1186/s12886-023-02780-0
 received in 2022-08-30, accepted in 2023-01-11,  发布年份 2023
来源: Springer
PDF
【 摘 要 】

BackgroundThe Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related macular degeneration (nAMD) suggested the importance of early and intensive dosing of ranibizumab for optimal treatment outcomes. This subgroup analysis aims to provide clinical information on treatment response that can potentially guide on maintaining the treatment or switching anti-VEGF agents in the real-world setting.MethodsVisual acuity (VA) and central retinal thickness (CRT) were assessed in the RACER subgroup population. Subgroup analysis sets were categorised based on: (1) baseline best-corrected VA (BCVA; ≤ 48 and > 48 letters); (2) baseline CRT (≤ 325 or > 325 μm); and (3) treatment response after three monthly initial injections: < or ≥ 5-letter gain in BCVA and reduction of < or ≥ 50 μm in CRT.ResultsPatient age, sex, nAMD duration and number of ranibizumab injections did not differ significantly between the treatment subgroups. Poor baseline BCVA (≤ 48 letters) and baseline CRT severity (> 325 µm) were predictors of maximum BCVA gains (9.6 ± 12.9 letters [95%CI: 6.3 to 12.9] and 5.1 ± 18.3 letters [95%CI: − 0.5 to 10.8] at Months 3 and 12, respectively) and better CRT reductions (− 127.6 ± 104.2 µm and − 104.2 ± 107.4 µm at Months 3 and 12, respectively; both P < 0.001). For the subgroup showing favourable treatment improvement with BCVA gains ≥ 5 letters after three monthly initial injections, 75.6% of patients maintained follow-up at Month 12 with a mean of 6.5 ± 14.3 letter gains (95% CI: 1.2 to 11.7). The BCVA gains < 5-letter subgroup nevertheless had stable BCVA (0.4 ± 12.1 letter gains) and CRT (− 41.9 ± 61.2 µm) at Month 12, respectively. In the subgroup with ≥ 50 µm CRT reduction after three monthly initial injections, there are significantly higher BCVA improvements vs. the < 50 µm CRT reduction subgroup at Month 3 (5.0 ± 8.6 letter gains vs. 1.5 ± 11.6 letter gains, respectively; intergroup P = 0.005).ConclusionLower baseline BCVA and higher baseline CRT were associated with BCVA gains and CRT reductions throughout the 12-month study period. Early CRT improvements after three monthly initial injections were associated with BCVA gains as early as Month 3.

【 授权许可】

CC BY   
© The Author(s) 2023

【 预 览 】
附件列表
Files Size Format View
RO202305114775264ZK.pdf 1862KB PDF download
Fig. 2 1878KB Image download
MediaObjects/41408_2022_766_MOESM3_ESM.pdf 219KB PDF download
Fig. 1 35KB Image download
42004_2022_800_Article_IEq73.gif 1KB Image download
MediaObjects/12888_2023_4533_MOESM1_ESM.docx 14KB Other download
【 图 表 】

42004_2022_800_Article_IEq73.gif

Fig. 1

Fig. 2

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  文献评价指标  
  下载次数:18次 浏览次数:0次